AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases. It also has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Inc. to develop and commercialize monospecific antibody product candidates targeting TIM-3 (TSR-022), LAG-3 (TSR-033), and PD-1 (TSR-042), as well as a bispecific antibody product candidate targeting PD-1 and LAG-3; and an inflammation partnership with Celgene Corporation to develop an anti-PD-1 agonist antibody (CC-90006) that is in Phase 1 trial. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is based in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-362-6295
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$10 million
Profitability
Miscellaneous
Employees60
OptionableOptionable
AnaptysBio (NASDAQ:ANAB) Frequently Asked Questions
What is AnaptysBio's stock symbol?
AnaptysBio trades on the NASDAQ under the ticker symbol "ANAB."
How were AnaptysBio's earnings last quarter?
AnaptysBio Inc (NASDAQ:ANAB) issued its earnings results on Thursday, November, 8th. The biotechnology company reported ($0.66) EPS for the quarter, beating the Zacks' consensus estimate of ($0.71) by $0.05. The biotechnology company earned $5 million during the quarter. View AnaptysBio's Earnings History.
When is AnaptysBio's next earnings date?
What price target have analysts set for ANAB?
10 equities research analysts have issued 12 month price objectives for AnaptysBio's stock. Their predictions range from $84.00 to $153.00. On average, they anticipate AnaptysBio's share price to reach $127.20 in the next year. This suggests a possible upside of 86.1% from the stock's current price. View Analyst Price Targets for AnaptysBio.
What is the consensus analysts' recommendation for AnaptysBio?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AnaptysBio in the last year. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AnaptysBio.
What are Wall Street analysts saying about AnaptysBio stock?
Here are some recent quotes from research analysts about AnaptysBio stock:
- 1. According to Zacks Investment Research, "AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California. " (1/16/2019)
- 2. HC Wainwright analysts commented, "Valuation and risks to our investment thesis. Our 12-month price target of $126/share is based on an equally weighted composite of (a) $90.5/share, as a 35x multiple of taxed and diluted FY32 GAAP EPS of $27.66 discounted back to and (b) an NPV of $161/share (discount rate 12.0%, growth rate 2.0%). The assumptions are in-line with the expected PE multiple and discount rate of an early development-stage biotechnology company." (12/20/2018)
- 3. Cantor Fitzgerald analysts commented, ". $140 price target. We think positive Dupixent phase 3 nasal polyp data from REGN (Neutral)/SNY (Not Covered) is an incremental positive for ANAB as it helps de-risk ANAB’s readout in this indication in 2H 2019. ANAB is also studying etokimab in chronic sinusitis with nasal polyps (CSwNP) and is guiding for phase 2 data in 2H19 (n=100, placebo controlled study). Because of the similarities in Dupixent and etokimab mechanisms of actions, we believe this should increase the likelihood of etokimab’s success in this study." (10/16/2018)
Has AnaptysBio been receiving favorable news coverage?
News articles about ANAB stock have trended positive recently, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. AnaptysBio earned a news sentiment score of 2.3 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the company's share price in the next few days.
Who are some of AnaptysBio's key competitors?
Some companies that are related to AnaptysBio include Nektar Therapeutics (NKTR), Loxo Oncology (LOXO), Marina Biotech (MRNA), Perrigo (PRGO), Catalent (CTLT), Dr.Reddy's Laboratories (RDY), Amarin (AMRN), GALAPAGOS NV/S (GLPG), United Therapeutics (UTHR), Patheon (PTHN), Alkermes (ALKS), Array Biopharma (ARRY), FibroGen (FGEN), GW Pharmaceuticals PLC- (GWPH) and Taro Pharmaceutical Industries (TARO).
Who are AnaptysBio's key executives?
AnaptysBio's management team includes the folowing people:
- Mr. Hamza Suria, Pres, CEO & Director (Age 43)
- Mr. Dominic G. Piscitelli M.B.A., CPA, Chief Financial Officer (Age 44)
- Prof. Marco Londei, Chief Medical Officer (Age 62)
- Dr. Margaret Marino Ph.D., VP of Project Management
- Mr. Peter Smith, VP of Commercial Strategy
When did AnaptysBio IPO?
(ANAB) raised $60 million in an initial public offering on Thursday, January 26th 2017. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Credit Suisse and Stifel acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
Who are AnaptysBio's major shareholders?
AnaptysBio's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.79%), Partner Fund Management L.P. (2.26%), Millennium Management LLC (0.97%), Northern Trust Corp (0.96%), Geode Capital Management LLC (0.95%) and Artal Group S.A. (0.56%). Company insiders that own AnaptysBio stock include Dominic Piscitelli, Hamza Suria, Holdings A/S Novo, Marco Londei, Nicholas Lydon and Ventures Vii L P Avalon. View Institutional Ownership Trends for AnaptysBio.
Which major investors are selling AnaptysBio stock?
ANAB stock was sold by a variety of institutional investors in the last quarter, including Partner Fund Management L.P., Artal Group S.A., Lord Abbett & CO. LLC, Two Sigma Advisers LP, Squarepoint Ops LLC, Partner Investment Management L.P., New York State Common Retirement Fund and Principal Financial Group Inc.. Company insiders that have sold AnaptysBio company stock in the last year include Dominic Piscitelli, Hamza Suria, Marco Londei and Nicholas Lydon. View Insider Buying and Selling for AnaptysBio.
Which major investors are buying AnaptysBio stock?
ANAB stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, BlackRock Inc., Advisor Group Inc., Dimensional Fund Advisors LP, Hudson Bay Capital Management LP, Northern Trust Corp, Fosun International Ltd and Tekla Capital Management LLC. View Insider Buying and Selling for AnaptysBio.
How do I buy shares of AnaptysBio?
Shares of ANAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AnaptysBio's stock price today?
One share of ANAB stock can currently be purchased for approximately $68.35.
How big of a company is AnaptysBio?
AnaptysBio has a market capitalization of $1.83 billion and generates $10 million in revenue each year. The biotechnology company earns $-30,070,000.00 in net income (profit) each year or ($1.52) on an earnings per share basis. AnaptysBio employs 60 workers across the globe.
What is AnaptysBio's official website?
How can I contact AnaptysBio?
AnaptysBio's mailing address is 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-362-6295 or via email at [email protected]
MarketBeat Community Rating for AnaptysBio (NASDAQ ANAB)
MarketBeat's community ratings are surveys of what our community members think about AnaptysBio and other stocks. Vote "Outperform" if you believe ANAB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANAB will underperform the S&P 500 over the long term. You may vote once every thirty days.
